Literature DB >> 9049181

Loss of heterozygosity on chromosome 9q21 (p16 gene) uncommon in soft-tissue sarcomas.

R Schneider-Stock1, K Radig, A Roessner.   

Abstract

Chromosome region 9p21 contains a tumor suppressor locus (p16) that may be involved in the genesis of several kinds of malignant tumors. To characterize the role of this gene in the development of soft-tissue tumors (STTs), we investigated the frequency of loss of heterozygosity (LOH) at this locus. DNA was obtained from 77 tumors and the peripheral blood of 23 of the patients with the tumors. Using one microsatellite marker distal to p16(D9S171) and one intragenic sequence-tagged site (STS) marker (c5.1), we observed LOH in only one liposarcoma and one malignant schwannoma (2.6%). Homozygous deletions of the p16 markers were not found. The osteosarcoma cell line MG-63 was used as a control for loss of the p16 gene. Because of the low LOH frequency, we hypothesize that the p16 gene is not essential for STT oncogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9049181     DOI: 10.1002/(sici)1098-2744(199702)18:2<63::aid-mc1>3.0.co;2-r

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  3 in total

1.  Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas.

Authors:  H P Kourea; I Orlow; B W Scheithauer; C Cordon-Cardo; J M Woodruff
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation.

Authors:  G P Nielsen; A O Stemmer-Rachamimov; Y Ino; M B Moller; A E Rosenberg; D N Louis
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Loss of p16INK4A expression is associated with allelic imbalance/loss of heterozygosity of chromosome 9p21 in microdissected synovial sarcomas.

Authors:  Muna Sabah; Robert Cummins; Mary Leader; Elaine Kay
Journal:  Virchows Arch       Date:  2005-08-05       Impact factor: 4.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.